Er-Kim, an international company specializing in the commercialization of novel therapies for pharmaceutical and biopharmaceutical companies, has signed a distribution agreement with the MEDICE Health Family, a developer and provider of innovative, integrated, and multimodal healthcare solutions, to commercialize Vafseo across Central & Eastern Europe (CEE).
Vafseo (vadadustat) is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor to treat anemia due to chronic kidney disease (CKD) for patients on chronic maintenance dialysis.
Under the agreement, Er-Kim is appointed as the exclusive distributor in Bulgaria, Croatia, Czechia, Hungary, Poland, Romania, Slovakia and Slovenia.
“As Er-Kim continues its mission to address global access inequities in pharmaceuticals, we are pleased to announce our partnership with the MEDICE Health Family on Vafseo®, aimed at delivering innovative treatments to patients in the CEE region,” said Cem Zorlular, CEO of Er-Kim.
He added: “Leveraging our leading expertise in nephrology and our established presence in the region, we are committed to providing patients with chronic kidney disease (CKD) and other kidney conditions with alternative treatment options. This partnership underscores our dedication to enhancing patient outcomes and broadening access to cutting-edge therapies.”
“We’re eager to bring Vafseo® to market across Central & Eastern Europe as we believe dialysis patients with anemia due to CKD could benefit from additional therapeutic options,” said Dr. Richard Ammer, Managing Partner of MEDICE.
